<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03801135</url>
  </required_header>
  <id_info>
    <org_study_id>MPFhemostaza</org_study_id>
    <nct_id>NCT03801135</nct_id>
  </id_info>
  <brief_title>Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation</brief_title>
  <official_title>A Prospective Interventional Study to Investigate Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation With or Without Coagulation Factors Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plasma exchange procedures remove procoagulant and anticoagulant factors. Every procedure
      increases the risk of bleeding and repeated procedures increase the risk of bleeding mostly
      because lower fibrinogen levels. The aim of study is to define coagulation status of patient
      after plasmapheresis with different laboratory tests and to investigate the possibility of
      fibrinogen concentrate replacement for the correction of induced coagulation disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Anticipated">September 24, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of plasmapheresis replacement fluid type on fibrinogen level</measure>
    <time_frame>Right after every plasmapheresis session, during the whole plasmapheresis treatment (usually about 2 weeks)]</time_frame>
    <description>Change of fibrinogen level after plasmapheresis treatment depending on replacement fluid type</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on coagulation tests after plasmapheresis - ROTEM EXTEM</measure>
    <time_frame>Right after every plasmapheresis session, during the whole plasmapheresis treatment (usually about 2 weeks)]</time_frame>
    <description>ROTEM (EXTEM MCF) change after plasmapheresis treatment depending on replacement fluid type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on coagulation tests after plasmapheresis - ROTEM FIBTEM</measure>
    <time_frame>Right after every plasmapheresis session, during the whole plasmapheresis treatment (usually about 2 weeks)]</time_frame>
    <description>ROTEM (FIBTEM MCF) change after plasmapheresis treatment depending on replacement fluid type</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Humoral Rejection</condition>
  <condition>Guillain-Barre Syndrome</condition>
  <condition>Miller Fisher Syndrome</condition>
  <condition>CIDP</condition>
  <condition>Good Pasture Syndrome</condition>
  <condition>Hyperviscosity Syndrome</condition>
  <arm_group>
    <arm_group_label>Electrolyte&amp;Albumin Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrinogen Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin. Fibrinogen concentrate will be infused afterwards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFP Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution, albumin and fresh frozen plasma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrinogen concentrate</intervention_name>
    <description>Haemocomplettan will be infused after plasma exchange procedure</description>
    <arm_group_label>Fibrinogen Treatment Group</arm_group_label>
    <other_name>Haemocomplettan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fresh Frozen Plasma</intervention_name>
    <description>Fresh frozen plasma will be part of replacement fluid</description>
    <arm_group_label>FFP Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Every patient who will need repeated plasmapheresis treatment in UKC Ljubljana

        Exclusion Criteria:

          -  pregnancy

          -  coagulation disorders

          -  Hypertriglyceridemia-induced acute pancreatitis

          -  hepatic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matej Zrimsek</last_name>
    <phone>+38631789714</phone>
    <email>matej.zrimsek@kclj.si</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <state>Gorenjska</state>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matej Zrimsek</last_name>
      <phone>+38631789714</phone>
      <email>matej.zrimsek@kclj.si</email>
    </contact>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Matej Zrimsek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fibrinogen concentrate</keyword>
  <keyword>Fresh frozen plasma</keyword>
  <keyword>ROTEM</keyword>
  <keyword>Fibrinogen</keyword>
  <keyword>Overall coagulation potential</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Glomerular Basement Membrane Disease</mesh_term>
    <mesh_term>Guillain-Barre Syndrome</mesh_term>
    <mesh_term>Miller Fisher Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

